{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:01:09Z","timestamp":1789876869816,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12328-025-02122-1","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:12:03Z","timestamp":1744283523000},"page":"520-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-8923","authenticated-orcid":false,"given":"Koshiro","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-1135","authenticated-orcid":false,"given":"Akiyoshi","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-2906","authenticated-orcid":false,"given":"Yasuyuki","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8627-5038","authenticated-orcid":false,"given":"Kenichiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-2055","authenticated-orcid":false,"given":"Hiromichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-5452","authenticated-orcid":false,"given":"Arisa","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-0282","authenticated-orcid":false,"given":"Takeshi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-1970","authenticated-orcid":false,"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-023X","authenticated-orcid":false,"given":"Yu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0672-7214","authenticated-orcid":false,"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"1","key":"2122_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA A Cancer J Clin."},{"issue":"4","key":"2122_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/hbsn.2018.03.16","volume":"7","author":"EW Beal","year":"2018","unstructured":"Beal EW, Tumin D, Moris D, et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2018;7(4):270\u20136.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"2122_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","volume":"16","author":"KJ Yao","year":"2016","unstructured":"Yao KJ, Jabbour S, Parekh N, Lin Y, Moss RA. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016;16(1):117.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"2122_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396.","journal-title":"Ann Surg"},{"issue":"10372","key":"2122_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195\u2013203.","journal-title":"Lancet"},{"issue":"5","key":"2122_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2122_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30(1):102\u201310.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2122_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015d","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2200015d.","journal-title":"NEJM Evid"},{"issue":"34","key":"2122_CR9","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.12998\/wjcc.v12.i34.6721","volume":"12","author":"Y Igata","year":"2024","unstructured":"Igata Y, Kudo M, Kojima M, et al. Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report. World J Clin Cases. 2024;12(34):6721\u20137.","journal-title":"World J Clin Cases."},{"issue":"9","key":"2122_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929\u201338.","journal-title":"Ann Oncol"},{"issue":"7","key":"2122_CR11","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.21873\/anticanres.17135","volume":"44","author":"H Okabe","year":"2024","unstructured":"Okabe H, Masuda T, Nitta H, et al. Advanced cholangiocarcinoma with high tumor mutation burden achieving complete response to immune check point inhibitor. Anticancer Res. 2024;44(7):3199\u2013203.","journal-title":"Anticancer Res"},{"key":"2122_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00572","volume":"8","author":"MD Robinson","year":"2024","unstructured":"Robinson MD, Wheatley R, Foster L, et al. Intrahepatic cholangiocarcinoma with extrahepatic metastasis and high tumor mutation burden: case of complete pathological response to cisplatin\/gemcitabine\/pembrolizumab. JCO Precis Oncol. 2024;8: e2300572.","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"2122_CR13","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1097\/JS9.0000000000001540","volume":"110","author":"S Wang","year":"2024","unstructured":"Wang S, Wang Y, Zhu C, et al. Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study. Int J Surg. 2024;110(8):4608\u201316.","journal-title":"Int J Surg."},{"issue":"1","key":"2122_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.2009.01230.x","volume":"76","author":"H Lynch","year":"2009","unstructured":"Lynch H, Lynch P, Lanspa S, Snyder C, Lynch J, Boland C. Review of the lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1\u201318. https:\/\/doi.org\/10.1111\/j.1399-0004.2009.01230.x.","journal-title":"Clin Genet"},{"issue":"1","key":"2122_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ng.283","volume":"41","author":"MJL Ligtenberg","year":"2009","unstructured":"Ligtenberg MJL, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. Heritable somatic methylation and inactivation of MSH2 in families with lynch syndrome due to deletion of the 3\u2032 exons of TACSTD1. Nat Genet. 2009;41(1):112\u20137. https:\/\/doi.org\/10.1038\/ng.283.","journal-title":"Nat Genet"},{"issue":"2","key":"2122_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/humu.20942","volume":"30","author":"ME Kovacs","year":"2009","unstructured":"Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to lynch syndrome. Hum Mutation. 2009;30(2):197\u2013203. https:\/\/doi.org\/10.1002\/humu.20942.","journal-title":"Hum Mutation."},{"issue":"7","key":"2122_CR17","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","volume":"67","author":"P M\u00f8ller","year":"2018","unstructured":"M\u00f8ller P, Sepp\u00e4l\u00e4 TT, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective lynch syndrome database. Gut. 2018;67(7):1306\u201316. https:\/\/doi.org\/10.1136\/gutjnl-2017-314057.","journal-title":"Gut"},{"key":"2122_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/cncr.2820690508","volume":"5","author":"JP Mecklin","year":"1992","unstructured":"Mecklin JP, J\u00e4rvinen HJ, Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer. 1992;5:1112\u20134. https:\/\/doi.org\/10.1002\/cncr.2820690508.","journal-title":"Cancer"},{"issue":"9","key":"2122_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/jnci\/djy004","volume":"110","author":"G-C Liu","year":"2018","unstructured":"Liu G-C, Liu R-Y, Yan J-P, et al. The heterogeneity between lynch-associated and sporadic MMR deficiency in colorectal cancers. J Natl Cancer Inst. 2018;110(9):975\u201384. https:\/\/doi.org\/10.1093\/jnci\/djy004.","journal-title":"J Natl Cancer Inst."},{"issue":"12","key":"2122_CR20","doi-asserted-by":"publisher","first-page":"6870","DOI":"10.1073\/pnas.95.12.6870","volume":"95","author":"JG Herman","year":"1998","unstructured":"Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95(12):6870\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2122_CR21","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","volume":"96","author":"M Toyota","year":"1999","unstructured":"Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 1","key":"2122_CR22","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.suronc.2007.10.018","volume":"16","author":"G Dionigi","year":"2007","unstructured":"Dionigi G, Bianchi V, Villa F, et al. Differences between familial and sporadic forms of colorectal cancer with DNA microsatellite instability. Surg Oncol. 2007;16(suppl 1):S37\u201342.","journal-title":"Surg Oncol."},{"issue":"6","key":"2122_CR23","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0002-9440(10)63062-3","volume":"159","author":"J Young","year":"2001","unstructured":"Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol. 2001;159(6):2107\u201316.","journal-title":"Am J Pathol"},{"issue":"11","key":"2122_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djr153","volume":"103","author":"FA Sinicrope","year":"2011","unstructured":"Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracilbased adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863\u201375.","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"2122_CR25","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andre","year":"2015","unstructured":"Andre T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC Study. J Clin Oncol. 2015;33(35):4176\u201387.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2122_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2014.09.041","volume":"148","author":"FA Sinicrope","year":"2015","unstructured":"Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148(1):88\u201399.","journal-title":"Gastroenterology"},{"issue":"3","key":"2122_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clcc.2016.11.001","volume":"16","author":"AK Alex","year":"2017","unstructured":"Alex AK, Siqueira S, Coudry R, et al. Response to chemotherapy and prognosis in metastatic colorectal cancer with DNA deficient mismatch repair. Clin Colorectal Cancer. 2017;16(3):228\u201339.","journal-title":"Clin Colorectal Cancer"},{"issue":"10","key":"2122_CR28","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","volume":"55","author":"PMK Westtcott","year":"2023","unstructured":"Westtcott PMK, Muyas F, Hauck H, et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nat Genet. 2023;55(10):1686\u201395. https:\/\/doi.org\/10.1038\/s41588-023-01499-4.","journal-title":"Nat Genet"},{"issue":"8","key":"2122_CR29","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid."},{"issue":"10391","key":"2122_CR30","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet."},{"issue":"5","key":"2122_CR31","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/cas.16121","volume":"115","author":"MK Kato","year":"2024","unstructured":"Kato MK, Fujii E, Asami Y, et al. Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer. Cancer Sci. 2024;115(5):1646\u201355. https:\/\/doi.org\/10.1111\/cas.16121.","journal-title":"Cancer Sci."},{"issue":"12","key":"2122_CR32","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23(12):3012\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2554.","journal-title":"Clin Cancer Res."},{"issue":"22","key":"2122_CR33","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","volume":"24","author":"J Biton","year":"2018","unstructured":"Biton J, Mansuet-Lupo A, P\u00e9cuchet N, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma. Clin Cancer Res. 2018;24(22):5710\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0163.","journal-title":"Clin Cancer Res."},{"issue":"22","key":"2122_CR34","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-18-0573","volume":"24","author":"DC Deniger","year":"2018","unstructured":"Deniger DC, Pasetto A, Robbins PF, et al. T-cell responses to TP53 \u201cHotspot\u201d mutations and unique neoantigens expressed by human ovarian cancers. Clin Cancer Res. 2018;24(22):5562\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0573.","journal-title":"Clin Cancer Res."},{"issue":"21","key":"2122_CR35","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024;390(21):1949\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2400634.","journal-title":"N Engl J Med."}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02122-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T07:28:49Z","timestamp":1747812529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02122-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2122"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02122-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient provided informed consent for the publication of this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}